Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

1.

Immediate Reconstruction with Autologous fat Transfer Following Breast-Conserving Surgery.

Biazus JV, Falcão CC, Parizotto AC, Stumpf CC, Cavalheiro JA, Schuh F, Cericatto R, Zucatto ÂE, Melo MP.

Breast J. 2015 May-Jun;21(3):268-75. doi: 10.1111/tbj.12397. Epub 2015 Mar 17.

PMID:
25783210
2.

Clinical and genetic characterization of basal cell carcinoma and breast cancer in a single patient.

Morelle A, Cericatto R, Krepischi AC, Ruiz IR.

Springerplus. 2014 Aug 22;3:454. doi: 10.1186/2193-1801-3-454. eCollection 2014.

3.

Sexual function and chemotherapy in postmenopausal women with breast cancer.

Cavalheiro JA, Bittelbrunn A, Menke CH, Biazús JV, Xavier NL, Cericatto R, Schuh F, Pinheiro CV, Passos EP.

BMC Womens Health. 2012 Sep 11;12:28.

4.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.

5.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4.

PMID:
21892704
6.

Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.

Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD; International Breast Cancer Study Group and BIG 1-98 Collaborative Group.

Breast Cancer Res. 2011 May 26;13(3):209. doi: 10.1186/bcr2837. Review.

7.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS.

N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.

8.

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group.

Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.

9.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033. Epub 2009 May 27.

10.

Progesterone receptors A and B and estrogen receptor alpha expression in normal breast tissue and fibroadenomas.

Branchini G, Schneider L, Cericatto R, Capp E, Brum IS.

Endocrine. 2009 Jun;35(3):459-66. doi: 10.1007/s12020-009-9176-0. Epub 2009 Apr 15.

PMID:
19367380
11.

Gene and protein expression of p53 and p21 in fibroadenomas and adjacent normal mammary tissue.

Schneider L, Branchini G, Cericatto R, Capp E, Brum IS.

Endocrine. 2009 Feb;35(1):118-22. doi: 10.1007/s12020-008-9124-4. Epub 2008 Nov 11.

PMID:
19002614
12.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98.

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.

13.

Tumor size as a surrogate end point for the detection of early breast cancer: a 30-year (1972-2002), single-center experience in southern Brazil.

Menke CH, Pohlmann PR, Backes A, Cericatto R, Oliveira M, Bittelbrunn A, Schwartsmann G.

Breast J. 2007 Sep-Oct;13(5):448-56.

PMID:
17760665
14.
15.

Effects of tamoxifen on serum prolactin levels, pituitary immunoreactive prolactin cells and uterine growth in estradiol-treated ovariectomized rats.

Spritzer PM, Ribeiro MF, Oliveira MC, Barbosa-Coutinho LM, Silva IS, Dahlem N, Cericatto R, Pavanato MA.

Horm Metab Res. 1996 Apr;28(4):171-6.

PMID:
8740191
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk